Navigation Links
VIA Pharmaceuticals Complies With NASDAQ Rule
Date:3/28/2008

SAN FRANCISCO, March 28 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and filed with the Securities and Exchange Commission on March 28, 2008 contained an explanatory paragraph relating to the Company's ability to continue as a going concern. The disclosure in this press release is required under the above NASDAQ rule and does not represent any change to the Company's Annual Report on Form 10-K filed on March 28, 2008 with the Securities and Exchange Commission.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Core Informatics Completes Successful LIMS Implementation for Progenics Pharmaceuticals
2. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
3. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
4. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
5. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
8. SGX Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
9. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
10. LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series C Financing Round
11. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... Texas (PRWEB) July 24, 2014 ... Potassium Sulphate Industry” is a professional and in-depth ... report introduces Potassium Sulphate basic information, including ... and industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) -- ... and monetization of intellectual property, today announced that the ... ending June 30, 2014 on Monday, August 18, 2014 ... 10 a.m. ET on Monday, August 18, 2014 to ... by the company,s CEO, Anthony Hayes . ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Spherix Schedules Shareholder Update Call 2
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... an agreement-in-principle to ensure the valorization and the operation under ... Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for human ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de Montreal ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ... pharmaceuticals in China, today reported,unaudited financial results for the quarter ... -- Total revenue increased to RMB442.5 million ... first quarter of 2009 from RMB394.6 million for the corresponding, ...
Cached Biology Technology:Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 2Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 3Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 4Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 5Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 6Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 7Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 8Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 9Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 10Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results 11
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire-iReach/ -- ... managing data from cardiac devices, has cut emergency room ... the UC San Diego (UCSD) Medical Center, according to ... Journal. The UCSD Emergency Departments are using the suite ... such as pacemakers or defibrillators. "Using Geneva,s ...
(Date:7/24/2014)... for food or commercial food sale, has been heavily ... of many species of primates and other mammals. ... of the species being consumed are birds, particularly large ... the meat made available for sale but the meat ... and brought to villages for consumption, we noted a ...
(Date:7/24/2014)... different effects on different species of fish, according ... Bristol and Exeter which tested fish anti-predator behaviour. ... flying seagull predator model when exposed to additional ... minnows. , Lead author Dr Irene Voellmy ... levels in many aquatic environments have increased substantially ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... documents dating back 3,500 years say they have found ... ancient Egypt and not with Hippocrates and the Greeks. ... Biomedical Egyptology at The University of Manchester discovered the ... before Hippocrates was born. , "Classical scholars have ...
... and Gail Williams and Stockholm University's Professor Robin Room examined ... and 2002. , Their results were published in the ... Review. , The men were categorised according to ... is a marker for lower socio-economic status (SES). ...
... Investigator, and Nancy Bae, Ph.D., Postdoctoral Research Associate ... offering insight into the way cells protect chromosome ... tomorrow's issue of Molecular Cell, their paper entitled ... Human Telomeric DNA Ends" employed a biochemical assay ...
Cached Biology News:Egyptians, not Greeks were true fathers of medicine 2Double the death rate from cirrhosis for 'blue collar' men 2Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Clone/PAD: ZMD.467. Immunogen: Synthetic ... of the human rat mouse dog ... Specific for the human occludin protein. ... cell lysates). Reactivity with rat ...
...
... Biochain's plant total protein ... for rapidly screening tissue specific ... Human placenta total protein is ... an interblot control for comparison ...
Biology Products: